Biotech Catalyst Calendar
Upcoming FDA decisions, advisory committees, EMA CHMP opinions, clinical-trial readouts and earnings for the next 14 days. Every date links to its primary source. Updated daily from official registries.
Month pages: PDUFA October 2026 · CHMP October 2026 · What do these events mean?
Friday, October 23, 2026
Tuesday, October 27, 2026
Wednesday, October 28, 2026
- CT ABOS Acumen Pharmaceuticals, Inc. Trial Readout: PHASE2 - Alzheimer Disease 2026-10-28
- Trial readout AFX.DE Carl Zeiss Meditec AG Trial Readout: NA - Corneal Diseases, Retinal Diseases ~ 2026-10-28
- CT ARWR Arrowhead Pharmaceuticals, Inc. Trial Readout: PHASE1, PHASE2 - Obesity, Diabetes Mellitus, Type 2 2026-10-28
- CT BCRX BioCryst Pharmaceuticals, Inc. Trial Readout: PHASE1 - Netherton Syndrome 2026-10-28
- Trial readout CLDX Celldex Therapeutics, Inc. Trial Readout: PHASE3 - Chronic Spontaneous Urticaria 2026-10-28
- Trial readout CRNX Crinetics Pharmaceuticals, Inc. Trial Readout: PHASE1/PHASE2 - Cushing Syndrome, Cushing Disease ~ 2026-10-28
- Trial readout FME.DE Fresenius Medical Care AG Trial Readout: N/A - Extracorporeal Membrane Oxygenation Complication, Neonatal Aspiration Pneumonia ~ 2026-10-28
- CT HALO Halozyme Therapeutics, Inc. Trial Readout: NA - Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma 2026-10-28
- CT HUMA Humacyte, Inc. Trial Readout: PHASE3 - End Stage Renal Disease (ESRD) 2026-10-28
- Trial readout IBRX ImmunityBio, Inc. Trial Readout: PHASE2 - Long COVID ~ 2026-10-28
- CT IDYA IDEAYA Biosciences, Inc. Trial Readout: PHASE1 - Advanced or Metastatic Solid Tumors, Breast Cancer 2026-10-28
- CT IMVT Immunovant, Inc. Trial Readout: PHASE2 - Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus 2026-10-28
- CT INCY Incyte Corporation Trial Readout: PHASE2 - Hidradenitis Suppurativa 2026-10-28
- CT IRON Disc Medicine, Inc. Trial Readout: PHASE2 - Inflammatory Bowel Disease (IBD), Anemia 2026-10-28
- Trial readout IRWD Ironwood Pharmaceuticals, Inc. Trial Readout: NA - Irritable Bowel Syndrome With Constipation ~ 2026-10-28
- Trial readout JANX Janux Therapeutics Trial Readout: EARLY_PHASE1 - Autoimmune ~ 2026-10-28
- CT MIRM Mirum Pharmaceuticals, Inc. Trial Readout: PHASE3 - Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) 2026-10-28
- CT MPLT MapLight Therapeutics, Inc. Trial Readout: PHASE2 - Autism Spectrum Disorder 2026-10-28
- Trial readout NRC National Research Corporation Trial Readout: NA - Respiratory Failure, Family Support 2026-10-28
- Trial readout PHAT Phathom Pharmaceuticals, Inc. Trial Readout: PHASE2 - Eosinophilic Esophagitis ~ 2026-10-28
- Trial readout PHIL.MI Philogen S.p.A. Trial Readout: PHASE1/PHASE2 - Glioblastoma ~ 2026-10-28
- Trial readout REGN Regeneron Pharmaceuticals, Inc. Trial Readout: PHASE2 - Melanoma, Head and Neck Squamous Cell Carcinoma ~ 2026-10-28
- Trial readout RGNX REGENXBIO Inc. Trial Readout: PHASE3 - AMD, nAMD ~ 2026-10-28
- CT RPTX Repare Therapeutics Inc. Trial Readout: PHASE1 - Advanced Solid Tumor 2026-10-28
- CT SNDX Syndax Pharmaceuticals, Inc. Trial Readout: PHASE1 - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia 2026-10-28
- Trial readout VTRS Viatris Inc. Trial Readout: N/A - Mild to Moderate Atopic Dermatitis ~ 2026-10-28
- CT XENE Xenon Pharmaceuticals Inc. Trial Readout: PHASE3 - Focal Onset Seizures 2026-10-28
- + 6 earnings reports this day — see the interactive calendar
Friday, October 30, 2026
- Trial readout BNTX BioNTech SE Trial Readout: PHASE1/PHASE2 - TNBC 2026-10-30
- Trial readout ILMN Illumina, Inc. Trial Readout: PHASE2 - Heart Failure, Ischemic Cardiomyopathy 2026-10-30
- CT INBX Inhibrx Biosciences, Inc. Trial Readout: PHASE1, PHASE2 - Solid Tumor, Non-Small Cell Lung Cancer 2026-10-30
- CT MBX MBX Biosciences, Inc. Trial Readout: PHASE1 - Obesity 2026-10-30
- Trial readout SNY Sanofi Trial Readout: PHASE2 - Gaucher Disease Type 1, Gaucher Disease Type 3 2026-10-30
- + 2 earnings reports this day — see the interactive calendar
Saturday, October 31, 2026
- Trial readout AMGN Amgen Inc. Trial Readout: PHASE2 - MTAP-deleted NSCLC 2026-10-31
- CT AMRX Amneal Pharmaceuticals, Inc. Trial Readout: N/A - Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases 2026-10-31
- Trial readout ANNX Annexon, Inc. Trial Readout: PHASE3 - Geographic Atrophy 2026-10-31
- CT BIIB Biogen Inc. Trial Readout: N/A - Multiple Sclerosis 2026-10-31
- Trial readout DXCM DexCom, Inc. Trial Readout: NA - Type 1 Diabetes 2026-10-31
- Trial readout MRK.DE Merck KGaA Trial Readout: PHASE1 - Healthy, Hepatic Impairment 2026-10-31
- Trial readout NTRA Natera, Inc. Trial Readout: N/A - Heart Transplant Rejection 2026-10-31
- Trial readout OLMA Olema Pharmaceuticals, Inc. Trial Readout: PHASE3 - Breast Cancer, Advanced Breast Cancer 2026-10-31
- CT RCUS Arcus Biosciences, Inc. Trial Readout: PHASE2 - Non Small Cell Lung Cancer, Non-small Cell Carcinoma 2026-10-31
- CT RYTM Rhythm Pharmaceuticals, Inc. Trial Readout: PHASE2 - Prader-Willi Syndrome, Obesity 2026-10-31
- Trial readout SRPT Sarepta Therapeutics, Inc. Trial Readout: PHASE3 - Muscular Dystrophy, Duchenne 2026-10-31
- Trial readout SYRE Spyre Therapeutics, Inc. Trial Readout: PHASE2 - Rheumatoid Arthritis, Psoriatic Arthritis 2026-10-31
- CT TGTX TG Therapeutics, Inc. Trial Readout: PHASE3 - Relapsing Multiple Sclerosis 2026-10-31
Sunday, November 1, 2026
- PDUFA decision AGIO Agios Pharmaceuticals, Inc. PDUFA target action date: Agios Pharmaceuticals, Inc. 2026-11-01
- Trial readout ERAS Erasca, Inc. Trial Readout: PHASE1/PHASE2 - Advanced or Metastatic Solid Tumors 2026-11-01
- Trial readout GILD Gilead Sciences, Inc. Trial Readout: PHASE2 - NSCLC Stage IV, Brain Metastases, Adult 2026-11-01
Monday, November 2, 2026
- Trial readout NOVO-B.CO Novo Nordisk A/S Trial Readout: N/A - Obesity, Type 2 Diabetes (T2D) 2026-11-02
- + 11 earnings reports this day — see the interactive calendar
Wednesday, November 4, 2026
- Trial readout LUN.CO H. Lundbeck A/S Trial Readout: PHASE1 - Healthy Participants 2026-11-04
- + 28 earnings reports this day — see the interactive calendar
Thursday, November 5, 2026
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.